MetaVia Inc., a clinical-stage biotech focused on cardiometabolic diseases including obesity and MASH, leverages a powerful portfolio of patents licensed exclusively from Dong-A ST to safeguard its lead candidates DA-1726 and vanoglipel through 2041 and 2035 respectively. Positive Phase 1 and Phase 2a trial data reveal promising safety, tolerability, and efficacy signals such as weight loss and metabolic improvements that underpin the company’s scientific prospects. However, enduring operating losses with net income at negative $13 million in 2025 highlight ongoing financial constraints, compounded by auditor doubts over going concern status. MetaVia depends on raising additional capital to support upcoming higher-dose titration clinical studies and broader development programs. Its moat remains tied closely to intellectual property strength and successful regulatory pathways.